An Introduction to Genitourinary Cancers
Genitourinary cancers incorporate the sub-specialities of prostate, kidney, bladder and testicular cancer. Advances in immunotherapies, targeted therapies and combination therapies have improved patient outcomes over recent years.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes, view our expert-led learning activities.
Genitourinary Cancers Content
Improving outcomes in prostate cancer: What is the role of PARP-inhibitor combination therapy?
Watch Dr Neal Shore discuss the use of PARP inhibitors for patients with mCRPC and consider their potential as combination treatment with androgen deprivation therapy.
- Discuss the use of combination PARP-inhibitor targeted therapy in the management of prostate cancer
- Evaluate how to select/identify patients for potential combination PARPi and androgen receptor targeted therapy for prostate cancer
- Review ongoing clinical trials exploring combination PARPi and androgen-receptor targeted therapy for prostate cancer
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic […]
Alison Birtle, ASCO GU 2021: Peri-operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer
touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance […]
Antibody-drug conjugates for solid tumours: Current understanding and future directions
Watch Prof. Giuseppe Curigliano discuss the latest advances in the antibody-drug conjugates for the treatment of solid tumours.
- Evaluate the efficacy and safety data for emerging ADCs in solid tumours
- Discuss how emerging ADCs may be incorporated into the treatment paradigm for patients with solid tumours
- Summarise novel ADCs and the ongoing clinical trials in patients with solid tumours
Testicular Choriocarcinoma with Inexplicably High Beta-human Chorionic Gonadotropin and Renal Metastases
Oncology & Hematology Review (US). 2020;16(2):124-6 DOI: https://doi.org/10.17925/OHR.2021.16.2.124
Choriocarcinoma of the testes is very rare, occurring either in pure form or as part of mixed germ cell tumor.1,2 Pure choriocarcinoma constitutes <1% of choriocarcinoma cases, whereas mixed tumors with choriocarcinoma make up 8% of testicular germ cell tumors.2 The overall incidence of choriocarcinoma is 0.8 cases per 100,000 male population in countries with highest frequency […]
Evolving Therapies for Urothelial Carcinoma—Novel Paradigms and Future Directions
Oncology & Hematology Review. 2020;16(2):82-9 DOI: https://doi.org/10.17925/OHR.2021.16.2.82
Urothelial carcinoma is the most common histologic type of bladder cancer in the USA and Europe, accounting for 90% of all bladder cancers. It is the sixth most common type of cancer diagnosed in the USA, and the 10th leading cause of cancer death, with an estimated 17,980 deaths predicted in 2020.1 Although the 5-year survival […]
The Role of High-Dose IL-2 in mRCC today
Watch leading experts discuss recent developments in checkpoint inhibitor therapy to treat mRCC,5,6 and the findings from a recent analysis of the PROCLAIMSM registry.
- Understand the importance of clinical risk factors in the treatment and management of mRCC and be aware of the current NCCN recommendations.
- Appreciate the clinical benefits and safety profile, including risks, of high-dose interleukin-2 therapy and how these may guide treatment decisions dependent on clinical risk factors.
- Demonstrate an awareness of the results of the CheckMate 214 study, showing differing survival and clinical response outcomes in patients with mRCC receiving checkpoint inhibitor therapy dependent on disease risk category.
- Understand the latest results from the PROCLAIMSM database, showing consistent survival benefits with high-dose interleukin-2 therapy across favorable, intermediate and poor-risk mRCC patients.
- Appreciate how these recent findings might alter the treatment paradigm for mRCC.
Antibody-drug conjugates for patients with solid tumours: Practical analysis of the latest data from ESMO 2020
Watch this two-part activity discussing the latest developments in antibody-drug conjugates for solid tumours. Filmed following presentations at ESMO 2020. Part 1: Watch internationally renowned expert Mikel Ross review key data from the congress Watch Now Part 2: Choose from leading experts who discuss what the latest data mean for global and regional practice Select An Interview
- Recognize the antibody drug conjugates (ADCs) that are available for the treatment of solid tumours
- Summarize how emerging and evolving ADCs may improve outcomes for patients with solid tumours
- Discuss practical strategies for the management of adverse events associated with approved ADCs for solid tumours
Ajjai Alva, ESMO 2020 – Pembrolizumab plus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma: the KEYNOTE-361 trial
Dr Ajjai Alva discusses the rationale of pembrolizumab in combination with chemotherapy for the treatment of advanced urothelial cancer and findings from the KEYNOTE-361, and future directions for pembrolizumab research. The late-breaking abstract ‘Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361’ (LBA23) was presented […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!